-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QE8C00QBAcwiC/tAHj+cr4sLYqB28/nFwRyawvSHRhkKP+L6R89RiSi4FZ1OXCWO L7kME22OLNV1yIre0QXDtA== 0000950123-09-063844.txt : 20091118 0000950123-09-063844.hdr.sgml : 20091118 20091118134351 ACCESSION NUMBER: 0000950123-09-063844 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20091118 DATE AS OF CHANGE: 20091118 GROUP MEMBERS: ANSBERT GADICKE GROUP MEMBERS: DENNIS HENNER GROUP MEMBERS: KURT WHEELER GROUP MEMBERS: LUKE EVNIN GROUP MEMBERS: MICHAEL STEINMETZ GROUP MEMBERS: MPM ASSET MANAGEMENT INVESTORS 2005 BVIII LLC GROUP MEMBERS: MPM BIOVENTURES III GMBH & CO BETEILIGUNGS KG GROUP MEMBERS: MPM BIOVENTURES III GP LP GROUP MEMBERS: MPM BIOVENTURES III LLC GROUP MEMBERS: MPM BIOVENTURES III PARALLEL FUND LP GROUP MEMBERS: MPM BIOVENTURES III QP LP GROUP MEMBERS: NICHOLAS GALAKATOS GROUP MEMBERS: NICHOLAS SIMON III SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PONIARD PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000755806 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911261311 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-40119 FILM NUMBER: 091192961 BUSINESS ADDRESS: STREET 1: 7000 SHORELINE COURT STREET 2: SUITE 270 CITY: SO. SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 2062862501 MAIL ADDRESS: STREET 1: 300 ELLIOTT AVENUE WEST STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98119-4114 FORMER COMPANY: FORMER CONFORMED NAME: NEORX CORP DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MPM BIOVENTURES III LP CENTRAL INDEX KEY: 0001173408 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: THE JOHN HANCOCK TOWER STREET 2: 200 CLARENDON STREET, 5TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617 425 9200 MAIL ADDRESS: STREET 1: THE JOHN HANCOCK TOWER STREET 2: 200 CLARENDON STREET, 5TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: MPM BIO VENTURES III LP DATE OF NAME CHANGE: 20020514 SC 13D/A 1 f54114sc13dza.htm AMENDMENT TO SCHEDULE 13D sc13dza

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 3)*

Poniard Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
640520300
(CUSIP Number)
Nicholas J. Simon
MPM Asset Management
The John Hancock Tower
200 Clarendon, 54th Floor
Boston, Massachusetts 02116
Telephone: (617) 425-9200
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
November 6, 2009
(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

 
 

 

                     
CUSIP No.
  
640520300 
 13D Page  
2 
   of   
26 
   Pages

 

           
1.   NAME OF REPORTING PERSONS I.R.S. Identification No(s). of above person(s) (entities only)

MPM BioVentures III, L.P.
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   þ (1)
     
3.   SEC USE ONLY
   
   
     
4.   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  WC
     
5.   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  7.   SOLE VOTING POWER
     
NUMBER OF   456,750(2)
       
SHARES 8.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0
       
EACH 9.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   456,750(2)
       
WITH: 10.   SHARED DISPOSITIVE POWER
     
    0
     
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  456,750(2)
     
12.   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  1.3%(3)
     
14.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  PN
(1) This Schedule is filed by MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG, MPM BioVentures III Parallel Fund, L.P., MPM BioVentures III GP, L.P., MPM BioVentures III LLC, and MPM Asset Management Investors 2005 BVIII LLC (collectively, the “MPM Entities”) and Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler (collectively, the “Listed Persons” and together with the MPM Entities, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D/A.
(2) Includes warrants to purchase 100,090 shares of common stock exercisable within 60 days of the date of this filing.
(3) This percentage is calculated based upon 36,747,210 shares of the Issuer’s common stock outstanding, as adjusted pursuant to Rule 13d-3(d)(1) promulgated under the Securities Exchange Act, which is the sum of: (i) 34,961,497 shares of the Issuer’s common stock outstanding on October 30, 2009, as set forth in the Issuer’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2009 and (ii) 1,785,713 shares of the Issuer’s common stock issuable upon the exercise of warrants held by the MPM Entities.

 

                     
CUSIP No.
  
640520300 
 13D Page  
3 
   of   
26 
   Pages

 

           
1.   NAME OF REPORTING PERSONS I.R.S. Identification No(s). of above person(s) (entities only)

MPM BioVentures III-QP, L.P.
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   þ (1)
     
3.   SEC USE ONLY
   
   
     
4.   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  WC
     
5.   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  7.   SOLE VOTING POWER
     
NUMBER OF   6,792,693(2)
       
SHARES 8.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0
       
EACH 9.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   6,792,693(2)
       
WITH: 10.   SHARED DISPOSITIVE POWER
     
    0
     
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  6,792,693(2)
     
12.   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  18.6%(3)
     
14.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  PN
(1) This Schedule is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D/A.
(2) Includes warrants to purchase 1,488,508 shares of common stock exercisable within 60 days of the date of this filing.
(3) This percentage is calculated based upon 36,747,210 shares of the Issuer’s common stock outstanding, as adjusted pursuant to Rule 13d-3(d)(1) promulgated under the Securities Exchange Act, which is the sum of: (i) 34,961,497 shares of the Issuer’s common stock outstanding on October 30, 2009, as set forth in the Issuer’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2009 and (ii) 1,785,713 shares of the Issuer’s common stock issuable upon the exercise of warrants held by the MPM Entities.

 

                     
CUSIP No.
  
640520300 
 13D Page  
4 
   of   
26 
   Pages

 

           
1.   NAME OF REPORTING PERSONS I.R.S. Identification No(s). of above person(s) (entities only)

MPM BioVentures III GmbH & Co. Beteiligungs KG
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   þ (1)
     
3.   SEC USE ONLY
   
   
     
4.   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  WC
     
5.   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  7.   SOLE VOTING POWER
     
NUMBER OF   574,011(2)
       
SHARES 8.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0
       
EACH 9.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   574,011(2)
       
WITH: 10.   SHARED DISPOSITIVE POWER
     
    0
     
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  574,011(2)
     
12.   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  1.6%(3)
     
14.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  PN
(1) This Schedule is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D/A.
(2) Includes warrants to purchase 125,785 shares of common stock exercisable within 60 days of the date of this filing.
(3) This percentage is calculated based upon 36,747,210 shares of the Issuer’s common stock outstanding, as adjusted pursuant to Rule 13d-3(d)(1) promulgated under the Securities Exchange Act, which is the sum of: (i) 34,961,497 shares of the Issuer’s common stock outstanding on October 30, 2009, as set forth in the Issuer’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2009 and (ii) 1,785,713 shares of the Issuer’s common stock issuable upon the exercise of warrants held by the MPM Entities.

 

                     
CUSIP No.
  
640520300 
 13D Page  
5 
   of   
26 
   Pages

 

           
1.   NAME OF REPORTING PERSONS I.R.S. Identification No(s). of above person(s) (entities only)

MPM BioVentures III Parallel Fund, L.P.
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   þ (1)
     
3.   SEC USE ONLY
   
   
     
4.   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  WC
     
5.   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  7.   SOLE VOTING POWER
     
NUMBER OF   205,189(2)
       
SHARES 8.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0
       
EACH 9.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   205,189(2)
       
WITH: 10.   SHARED DISPOSITIVE POWER
     
    0
     
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  205,189(2)
     
12.   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  0.6%(3)
     
14.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  PN
(1) This Schedule is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D/A.
(2) Includes warrants to purchase 44,964 shares of common stock exercisable within 60 days of the date of this filing.
(3) This percentage is calculated based upon 36,747,210 shares of the Issuer’s common stock outstanding, as adjusted pursuant to Rule 13d-3(d)(1) promulgated under the Securities Exchange Act, which is the sum of: (i) 34,961,497 shares of the Issuer’s common stock outstanding on October 30, 2009, as set forth in the Issuer’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2009 and (ii) 1,785,713 shares of the Issuer’s common stock issuable upon the exercise of warrants held by the MPM Entities.

 

                     
CUSIP No.
  
640520300 
 13D Page  
6 
   of   
26 
   Pages

 

           
1.   NAME OF REPORTING PERSONS I.R.S. Identification No(s). of above person(s) (entities only)

MPM BioVentures III GP, L.P.
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   þ (1)
     
3.   SEC USE ONLY
   
   
     
4.   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  WC
     
5.   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  7.   SOLE VOTING POWER
     
NUMBER OF   0
       
SHARES 8.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   8,028,643(2)
       
EACH 9.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0
       
WITH: 10.   SHARED DISPOSITIVE POWER
     
    8,028,643(2)
     
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  8,028,643(2)
     
12.   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  21.9%(3)
     
14.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  PN
(1) This Schedule is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D/A.
(2) Includes the following shares of common stock of the Issuer: 356,660 shares held by MPM BioVentures III, L.P., 5,304,185 shares held by MPM BioVentures III-QP, L.P., 448,226 shares held by MPM BioVentures III GmbH & Co. Beteiligungs KG and 160,225 shares held by MPM BioVentures III Parallel Fund, L.P. Also includes warrants to purchase shares of common stock exercisable within 60 days of the date of this filing as follows: 100,090 shares held by MPM BioVentures III, L.P., 1,488,508 shares held by MPM BioVentures III-QP, L.P., 125,785 share held by MPM BioVentures III GmbH & Co. Beteiligungs KG and 44,964 shares held by MPM BioVentures III Parallel Fund, L.P. MPM BioVentures III GP, L.P. and MPM BioVentures III LLC are the direct and indirect general partners of each of MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG and MPM BioVentures III Parallel Fund, L.P.
(3) This percentage is calculated based upon 36,747,210 shares of the Issuer’s common stock outstanding, as adjusted pursuant to Rule 13d-3(d)(1) promulgated under the Securities Exchange Act, which is the sum of: (i) 34,961,497 shares of the Issuer’s common stock outstanding on October 30, 2009, as set forth in the Issuer’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2009 and (ii) 1,785,713 shares of the Issuer’s common stock issuable upon the exercise of warrants held by the MPM Entities.

 

                     
CUSIP No.
  
640520300 
 13D Page  
7 
   of   
26 
   Pages

 

           
1.   NAME OF REPORTING PERSONS I.R.S. Identification No(s). of above person(s) (entities only)

MPM BioVentures III LLC
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   þ (1)
     
3.   SEC USE ONLY
   
   
     
4.   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  WC
     
5.   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  7.   SOLE VOTING POWER
     
NUMBER OF   0
       
SHARES 8.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   8,028,643(2)
       
EACH 9.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0
       
WITH: 10.   SHARED DISPOSITIVE POWER
     
    8,028,643(2)
     
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  8,028,643(2)
     
12.   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  21.9%(3)
     
14.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  OO
(1) This Schedule is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D/A.
(2) Includes the following shares of common stock of the Issuer: 356,660 shares held by MPM BioVentures III, L.P., 5,304,185 shares held by MPM BioVentures III-QP, L.P., 448,226 shares held by MPM BioVentures III GmbH & Co. Beteiligungs KG and 160,225 shares held by MPM BioVentures III Parallel Fund, L.P. Also includes warrants to purchase shares of common stock exercisable within 60 days of the date of this filing as follows: 100,090 shares held by MPM BioVentures III, L.P., 1,488,508 shares held by MPM BioVentures III-QP, L.P., 125,785 share held by MPM BioVentures III GmbH & Co. Beteiligungs KG and 44,964 shares held by MPM BioVentures III Parallel Fund, L.P. MPM BioVentures III GP, L.P. and MPM BioVentures III LLC are the direct and indirect general partners of each of MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG and MPM BioVentures III Parallel Fund, L.P.
(3) This percentage is calculated based upon 36,747,210 shares of the Issuer’s common stock outstanding, as adjusted pursuant to Rule 13d-3(d)(1) promulgated under the Securities Exchange Act, which is the sum of: (i) 34,961,497 shares of the Issuer’s common stock outstanding on October 30, 2009, as set forth in the Issuer’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2009 and (ii) 1,785,713 shares of the Issuer’s common stock issuable upon the exercise of warrants held by the MPM Entities.

 

                     
CUSIP No.
  
640520300 
 13D Page  
8 
   of   
26 
   Pages

 

           
1.   NAME OF REPORTING PERSONS I.R.S. Identification No(s). of above person(s) (entities only)

MPM Asset Management Investors 2005 BVIII LLC
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   þ (1)
     
3.   SEC USE ONLY
   
   
     
4.   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  WC
     
5.   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  7.   SOLE VOTING POWER
     
NUMBER OF   120,319(2)
       
SHARES 8.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0
       
EACH 9.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   120,319(2)
       
WITH: 10.   SHARED DISPOSITIVE POWER
     
    0
     
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  120,319(2)
     
12.   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  0.3%(3)
     
14.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  OO
(1) This Schedule is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D/A.
(2) Includes warrants to purchase 26,366 shares of common stock exercisable within 60 days of the date of this filing.
(3) This percentage is calculated based upon 36,747,210 shares of the Issuer’s common stock outstanding, as adjusted pursuant to Rule 13d-3(d)(1) promulgated under the Securities Exchange Act, which is the sum of: (i) 34,961,497 shares of the Issuer’s common stock outstanding on October 30, 2009, as set forth in the Issuer’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2009 and (ii) 1,785,713 shares of the Issuer’s common stock issuable upon the exercise of warrants held by the MPM Entities.

 

                     
CUSIP No.
  
640520300 
 13D Page  
9 
   of   
26 
   Pages

 

           
1.   NAME OF REPORTING PERSONS I.R.S. Identification No(s). of above person(s) (entities only)

Luke Evnin
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   þ (1)
     
3.   SEC USE ONLY
   
   
     
4.   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  WC
     
5.   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States
       
  7.   SOLE VOTING POWER
     
NUMBER OF   0
       
SHARES 8.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   8,148,962(2)
       
EACH 9.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0
       
WITH: 10.   SHARED DISPOSITIVE POWER
     
    8,148,962(2)
     
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  8,148,962(2)
     
12.   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  22.2%(3)
     
14.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IN
(1) This Schedule is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D/A.
(2) Includes the following shares of common stock of the Issuer: 356,660 shares held by MPM BioVentures III, L.P., 5,304,185 shares held by MPM BioVentures III-QP, L.P., 448,226 shares held by MPM BioVentures III GmbH & Co. Beteiligungs KG, 160,225 shares held by MPM BioVentures III Parallel Fund, L.P. and 93,953 shares held by MPM Asset Management Investors 2005 BVII LLC. Also includes warrants to purchase shares of common stock exercisable within 60 days of the date of this filing as follows: 100,090 shares held by MPM BioVentures III, L.P., 1,488,508 shares held by MPM BioVentures III-QP, L.P., 125,785 share held by MPM BioVentures III GmbH & Co. Beteiligungs KG, 44,964 shares held by MPM BioVentures III Parallel Fund, L.P. and 26,366 shares held by MPM Asset Management Investors 2005 BVIII LLC. MPM BioVentures III GP, L.P. and MPM BioVentures III LLC are the direct and indirect general partners of each of MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG and MPM BioVentures III Parallel Fund, L.P. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the Series A members of MPM BioVentures III LLC and the managers of MPM Asset Management Investors 2005 BVIII LLC.
(3) This percentage is calculated based upon 36,747,210 shares of the Issuer’s common stock outstanding, as adjusted pursuant to Rule 13d-3(d)(1) promulgated under the Securities Exchange Act, which is the sum of: (i) 34,961,497 shares of the Issuer’s common stock outstanding on October 30, 2009, as set forth in the Issuer’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2009 and (ii) 1,785,713 shares of the Issuer’s common stock issuable upon the exercise of warrants held by the MPM Entities.

 

                     
CUSIP No.
  
640520300 
 13D Page  
10 
   of   
26 
   Pages

 

           
1.   NAME OF REPORTING PERSONS I.R.S. Identification No(s). of above person(s) (entities only)

Ansbert Gadicke
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   þ (1)
     
3.   SEC USE ONLY
   
   
     
4.   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  WC
     
5.   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States
       
  7.   SOLE VOTING POWER
     
NUMBER OF   0
       
SHARES 8.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   8,148,962(2)
       
EACH 9.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0
       
WITH: 10.   SHARED DISPOSITIVE POWER
     
    8,148,962(2)
     
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  8,148,962(2)
     
12.   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  22.2%(3)
     
14.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IN
(1) This Schedule is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D/A.
(2) Includes the following shares of common stock of the Issuer: 356,660 shares held by MPM BioVentures III, L.P., 5,304,185 shares held by MPM BioVentures III-QP, L.P., 448,226 shares held by MPM BioVentures III GmbH & Co. Beteiligungs KG, 160,225 shares held by MPM BioVentures III Parallel Fund, L.P. and 93,953 shares held by MPM Asset Management Investors 2005 BVII LLC. Also includes warrants to purchase shares of common stock exercisable within 60 days of the date of this filing as follows: 100,090 shares held by MPM BioVentures III, L.P., 1,488,508 shares held by MPM BioVentures III-QP, L.P., 125,785 share held by MPM BioVentures III GmbH & Co. Beteiligungs KG, 44,964 shares held by MPM BioVentures III Parallel Fund, L.P. and 26,366 shares held by MPM Asset Management Investors 2005 BVIII LLC. MPM BioVentures III GP, L.P. and MPM BioVentures III LLC are the direct and indirect general partners of each of MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG and MPM BioVentures III Parallel Fund, L.P. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the Series A members of MPM BioVentures III LLC and the managers of MPM Asset Management Investors 2005 BVIII LLC.
(3) This percentage is calculated based upon 36,747,210 shares of the Issuer’s common stock outstanding, as adjusted pursuant to Rule 13d-3(d)(1) promulgated under the Securities Exchange Act, which is the sum of: (i) 34,961,497 shares of the Issuer’s common stock outstanding on October 30, 2009, as set forth in the Issuer’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2009 and (ii) 1,785,713 shares of the Issuer’s common stock issuable upon the exercise of warrants held by the MPM Entities.

 

                     
CUSIP No.
  
640520300 
 13D Page  
11 
   of   
26 
   Pages

 

           
1.   NAME OF REPORTING PERSONS I.R.S. Identification No(s). of above person(s) (entities only)

Nicholas Galakatos
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   þ (1)
     
3.   SEC USE ONLY
   
   
     
4.   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  WC
     
5.   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States
       
  7.   SOLE VOTING POWER
     
NUMBER OF   0
       
SHARES 8.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   8,148,962(2)
       
EACH 9.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0
       
WITH: 10.   SHARED DISPOSITIVE POWER
     
    8,148,962(2)
     
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  8,148,962(2)
     
12.   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  22.2%(3)
     
14.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IN
(1) This Schedule is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D/A.
(2) Includes the following shares of common stock of the Issuer: 356,660 shares held by MPM BioVentures III, L.P., 5,304,185 shares held by MPM BioVentures III-QP, L.P., 448,226 shares held by MPM BioVentures III GmbH & Co. Beteiligungs KG, 160,225 shares held by MPM BioVentures III Parallel Fund, L.P. and 93,953 shares held by MPM Asset Management Investors 2005 BVII LLC. Also includes warrants to purchase shares of common stock exercisable within 60 days of the date of this filing as follows: 100,090 shares held by MPM BioVentures III, L.P., 1,488,508 shares held by MPM BioVentures III-QP, L.P., 125,785 share held by MPM BioVentures III GmbH & Co. Beteiligungs KG, 44,964 shares held by MPM BioVentures III Parallel Fund, L.P. and 26,366 shares held by MPM Asset Management Investors 2005 BVIII LLC. MPM BioVentures III GP, L.P. and MPM BioVentures III LLC are the direct and indirect general partners of each of MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG and MPM BioVentures III Parallel Fund, L.P. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the Series A members of MPM BioVentures III LLC and the managers of MPM Asset Management Investors 2005 BVIII LLC.
(3) This percentage is calculated based upon 36,747,210 shares of the Issuer’s common stock outstanding, as adjusted pursuant to Rule 13d-3(d)(1) promulgated under the Securities Exchange Act, which is the sum of: (i) 34,961,497 shares of the Issuer’s common stock outstanding on October 30, 2009, as set forth in the Issuer’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2009 and (ii) 1,785,713 shares of the Issuer’s common stock issuable upon the exercise of warrants held by the MPM Entities.

 

                     
CUSIP No.
  
640520300 
 13D Page  
12 
   of   
26 
   Pages

 

           
1.   NAME OF REPORTING PERSONS I.R.S. Identification No(s). of above person(s) (entities only)

Dennis Henner
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   þ (1)
     
3.   SEC USE ONLY
   
   
     
4.   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  WC
     
5.   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States
       
  7.   SOLE VOTING POWER
     
NUMBER OF   0
       
SHARES 8.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   8,148,962(2)
       
EACH 9.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0
       
WITH: 10.   SHARED DISPOSITIVE POWER
     
    8,148,962(2)
     
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  8,148,962(2)
     
12.   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  22.2%(3)
     
14.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IN
(1) This Schedule is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D/A.
(2) Includes the following shares of common stock of the Issuer: 356,660 shares held by MPM BioVentures III, L.P., 5,304,185 shares held by MPM BioVentures III-QP, L.P., 448,226 shares held by MPM BioVentures III GmbH & Co. Beteiligungs KG, 160,225 shares held by MPM BioVentures III Parallel Fund, L.P. and 93,953 shares held by MPM Asset Management Investors 2005 BVII LLC. Also includes warrants to purchase shares of common stock exercisable within 60 days of the date of this filing as follows: 100,090 shares held by MPM BioVentures III, L.P., 1,488,508 shares held by MPM BioVentures III-QP, L.P., 125,785 share held by MPM BioVentures III GmbH & Co. Beteiligungs KG, 44,964 shares held by MPM BioVentures III Parallel Fund, L.P. and 26,366 shares held by MPM Asset Management Investors 2005 BVIII LLC. MPM BioVentures III GP, L.P. and MPM BioVentures III LLC are the direct and indirect general partners of each of MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P. , MPM BioVentures III GmbH & Co. Beteiligungs KG and MPM BioVentures III Parallel Fund, L.P. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the Series A members of MPM BioVentures III LLC and the managers of MPM Asset Management Investors 2005 BVIII LLC.
(3) This percentage is calculated based upon 36,747,210 shares of the Issuer’s common stock outstanding, as adjusted pursuant to Rule 13d-3(d)(1) promulgated under the Securities Exchange Act, which is the sum of: (i) 34,961,497 shares of the Issuer’s common stock outstanding on October 30, 2009, as set forth in the Issuer’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2009 and (ii) 1,785,713 shares of the Issuer’s common stock issuable upon the exercise of warrants held by the MPM Entities.

 

                     
CUSIP No.
  
640520300 
 13D Page  
13 
   of   
26 
   Pages

 

           
1.   NAME OF REPORTING PERSONS I.R.S. Identification No(s). of above person(s) (entities only)

Nicholas Simon III
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   þ (1)
     
3.   SEC USE ONLY
   
   
     
4.   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  WC
     
5.   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States
       
  7.   SOLE VOTING POWER
     
NUMBER OF   30,833(2)
       
SHARES 8.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   8,148,962(3)
       
EACH 9.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   30,833(2)
       
WITH: 10.   SHARED DISPOSITIVE POWER
     
    8,148,962(3)
     
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  8,179,795(2)(3)
     
12.   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  22.2%(4)
     
14.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IN
(1) This Schedule is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D/A.
(2) Represents options to purchase shares of common stock exercisable within 60 days of the date of this filing
(3) Includes the following shares of common stock of the Issuer: 356,660 shares held by MPM BioVentures III, L.P., 5,304,185 shares held by MPM BioVentures III-QP, L.P., 448,226 shares held by MPM BioVentures III GmbH & Co. Beteiligungs KG, 160,225 shares held by MPM BioVentures III Parallel Fund, L.P. and 93,953 shares held by MPM Asset Management Investors 2005 BVII LLC. Also includes warrants to purchase shares of common stock exercisable within 60 days of the date of this filing as follows: 100,090 shares held by MPM BioVentures III, L.P., 1,488,508 shares held by MPM BioVentures III-QP, L.P., 125,785 share held by MPM BioVentures III GmbH & Co. Beteiligungs KG, 44,964 shares held by MPM BioVentures III Parallel Fund, L.P. and 26,366 shares held by MPM Asset Management Investors 2005 BVIII LLC. MPM BioVentures III GP, L.P. and MPM BioVentures III LLC are the direct and indirect general partners of each of MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P. , MPM BioVentures III GmbH & Co. Beteiligungs KG and MPM BioVentures III Parallel Fund, L.P. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the Series A members of MPM BioVentures III LLC and the managers of MPM Asset Management Investors 2005 BVIII LLC.
(4) This percentage is calculated based upon 36,747,210 shares of the Issuer’s common stock outstanding, as adjusted pursuant to Rule 13d-3(d)(1) promulgated under the Securities Exchange Act, which is the sum of: (i) 34,961,497 shares of the Issuer’s common stock outstanding on October 30, 2009, as set forth in the Issuer’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2009 and (ii) 1,785,713 shares of the Issuer’s common stock issuable upon the exercise of warrants held by the MPM Entities.

 

                     
CUSIP No.
  
640520300 
 13D Page  
14 
   of   
26 
   Pages

 

           
1.   NAME OF REPORTING PERSONS I.R.S. Identification No(s). of above person(s) (entities only)

Michael Steinmetz
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   þ (1)
     
3.   SEC USE ONLY
   
   
     
4.   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  WC
     
5.   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  United States
       
  7.   SOLE VOTING POWER
     
NUMBER OF   0
       
SHARES 8.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   8,148,962(2)
       
EACH 9.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0
       
WITH: 10.   SHARED DISPOSITIVE POWER
     
    8,148,962(2)
     
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  8,148,962(2)
     
12.   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  22.2%(3)
     
14.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IN
(1) This Schedule is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D/A.
(2) Includes the following shares of common stock of the Issuer: 356,660 shares held by MPM BioVentures III, L.P., 5,304,185 shares held by MPM BioVentures III-QP, L.P., 448,226 shares held by MPM BioVentures III GmbH & Co. Beteiligungs KG, 160,225 shares held by MPM BioVentures III Parallel Fund, L.P. and 93,953 shares held by MPM Asset Management Investors 2005 BVII LLC. Also includes warrants to purchase shares of common stock exercisable within 60 days of the date of this filing as follows: 100,090 shares held by MPM BioVentures III, L.P., 1,488,508 shares held by MPM BioVentures III-QP, L.P., 125,785 share held by MPM BioVentures III GmbH & Co. Beteiligungs KG, 44,964 shares held by MPM BioVentures III Parallel Fund, L.P. and 26,366 shares held by MPM Asset Management Investors 2005 BVIII LLC. MPM BioVentures III GP, L.P. and MPM BioVentures III LLC are the direct and indirect general partners of each of MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG and MPM BioVentures III Parallel Fund, L.P. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the Series A members of MPM BioVentures III LLC and the managers of MPM Asset Management Investors 2005 BVIII LLC.
(3) This percentage is calculated based upon 36,747,210 shares of the Issuer’s common stock outstanding, as adjusted pursuant to Rule 13d-3(d)(1) promulgated under the Securities Exchange Act, which is the sum of: (i) 34,961,497 shares of the Issuer’s common stock outstanding on October 30, 2009, as set forth in the Issuer’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2009 and (ii) 1,785,713 shares of the Issuer’s common stock issuable upon the exercise of warrants held by the MPM Entities.

 

                     
CUSIP No.
  
640520300 
 13D Page  
15 
   of   
26 
   Pages

 

           
1.   NAME OF REPORTING PERSONS I.R.S. Identification No(s). of above person(s) (entities only)

Kurt Wheeler
     
     
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
  (a)   o 
  (b)   þ (1)
     
3.   SEC USE ONLY
   
   
     
4.   SOURCE OF FUNDS (SEE INSTRUCTIONS)
   
  WC
     
5.   CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
   
  o
     
6.   CITIZENSHIP OR PLACE OF ORGANIZATION
   
 
       
  7.   SOLE VOTING POWER
     
NUMBER OF   0
       
SHARES 8.   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   8,148,962(2)
       
EACH 9.   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   0
       
WITH: 10.   SHARED DISPOSITIVE POWER
     
    8,148,962(2)
     
11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  8,148,962(2)
     
12.   CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
13.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
   
  22.2%(3)
     
14.   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  IN
(1) This Schedule is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D/A.
(2) Includes the following shares of common stock of the Issuer: 356,660 shares held by MPM BioVentures III, L.P., 5,304,185 shares held by MPM BioVentures III-QP, L.P., 448,226 shares held by MPM BioVentures III GmbH & Co. Beteiligungs KG, 160,225 shares held by MPM BioVentures III Parallel Fund, L.P. and 93,953 shares held by MPM Asset Management Investors 2005 BVII LLC. Also includes warrants to purchase shares of common stock exercisable within 60 days of the date of this filing as follows: 100,090 shares held by MPM BioVentures III, L.P., 1,488,508 shares held by MPM BioVentures III-QP, L.P., 125,785 share held by MPM BioVentures III GmbH & Co. Beteiligungs KG, 44,964 shares held by MPM BioVentures III Parallel Fund, L.P. and 26,366 shares held by MPM Asset Management Investors 2005 BVIII LLC. MPM BioVentures III GP, L.P. and MPM BioVentures III LLC are the direct and indirect general partners of each of MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG and MPM BioVentures III Parallel Fund, L.P. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the Series A members of MPM BioVentures III LLC and the managers of MPM Asset Management Investors 2005 BVIII LLC.
(3) This percentage is calculated based upon 36,747,210 shares of the Issuer’s common stock outstanding, as adjusted pursuant to Rule 13d-3(d)(1) promulgated under the Securities Exchange Act, which is the sum of: (i) 34,961,497 shares of the Issuer’s common stock outstanding on October 30, 2009, as set forth in the Issuer’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2009 and (ii) 1,785,713 shares of the Issuer’s common stock issuable upon the exercise of warrants held by the MPM Entities.

 

     The following constitutes Amendment No. 3 to the Schedule 13D previously filed by the undersigned with the Securities and Exchange Commission on February 13, 2006, as subsequently amended by Amendment No. 2 filed on May 9, 2007 (as so amended, the “Schedule 13D/A”). The Schedule 13D/A is being filed in connection with the sale of shares pursuant to a Rule 10b5-1 sales plan entered into as of September 21, 2009 by the MPM Funds (as defined below).
     All capitalized terms not otherwise defined herein shall have the meaning ascribed to the terms in the Original Schedule 13D. The Original Schedule 13D is hereby further amended and supplemented as follows and, except as expressly amended below, the Original Schedule 13D remains in full force and effect.
Item 1. Security and Issuer.
     (a) This statement on Schedule 13D relates to the common stock, par value $0.02 per share, of Poniard Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”).
     (b) The principal executive offices of the Issuer are located at 7000 Shoreline Court, Suite 270, So. San Francisco, CA 94080.
Item 2. Identity and Background.
     (a) The persons filing this statement are MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG, MPM BioVentures III Parallel Fund, L.P. and MPM Asset Management Investors 2005 BVIII LLC (collectively, the “MPM Funds”), MPM BioVentures III GP, L.P. , MPM BioVentures III LLC (collectively with the MPM Funds and MPM BioVentures III GP, L.P., the “MPM Entities”) and Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler (collectively, the “Listed Persons” and together with the MPM Entities, the “Reporting Persons”).
     (b) The address of the principal place of business of each of the Reporting Persons is The John Hancock Tower, 200 Clarendon Street, 54 th Floor, Boston, Massachusetts 02116.
     (c) The principal business of each of the MPM Entities is the venture capital investment business. Each of the Listed Persons is a general partner of various venture capital investment funds.
     (d) During the last five years, none of the Reporting Persons, to the knowledge of the MPM Entities, has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).
     (e) During the last five years, none of the Reporting Persons, to the knowledge of the MPM Entities, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
     (f) Each of the MPM Entities is a Delaware limited partnership or limited liability company, with the exception of MPM BioVentures III GmbH & Co. Beteiligungs KG, which is a German limited partnership. Each of the Listed Persons is a citizen of the United States.
In accordance with the provisions of General Instruction C to Schedule 13D, information concerning the managers and each other person controlling the general partners of the MPM Entities required by Item 2 of Schedule 13D is listed on Schedule 1 hereto and is incorporated by reference herein.
Item 3. Source and Amount of Funds or Other Consideration.
     No change
Item 4. Purpose of Transaction.
     “Item 4. Purpose of Transaction” of the Original Schedule 13D is hereby amended by adding the following to the end thereof:
     On September 21, 2009, the MPM Funds entered into a plan to sell a portion of their holdings of the Issuer’s Common Stock (the “Plan”). Under the terms of the Plan, adopted in compliance with Rule 10b5-1 of the Securities Exchange Act of 1934, the Reporting Persons sold an aggregate of 494,962 shares of the Issuer’s Common Stock between November 5, 2009 and November 9, 2009.

 

 

Item 5. Interest in Securities of the Issuer.
     “Item 5. Interest in Securities of the Issuer” is hereby amended and restated in its entirety as follows:
     (a) — (b) The following information with respect to the ownership of the common stock of the Issuer by the Reporting Persons is provided as of November 13, 2009:
                                                                 
            Warrant/                            
            Option                            
            Shares   Sole   Shared   Sole   Shared           Percentage
    Shares Held   Held   Voting   Voting   Dispositive   Dispositive   Beneficial   of Class
MPM Entity   Directly   Directly   Power   Power   Power   Power   Ownership   (3)
MPM BioVentures III, L.P.
     356,660       100,090       456,750       0       456,750       0       456,750       1.3 %
MPM BioVentures III-QP, L.P.
     5,304,185       1,488,508       6,792,693       0       6,792,693       0       6,792,693       18.6 %
MPM BioVentures III GmbH & Co.
                                                                
Beteiligungs KG
     448,226       125,785       574,011       0       574,011       0       574,011       1.6 %
MPM BioVentures III Parallel Fund, L.P.
     160,225       44,964       205,189       0       205,189       0       205,189       0.6 %
MPM BioVentures III GP, L.P.(1)
     0       0       0       8,028,643       0       8,028,643       0       0.3 %
MPM BioVentures III LLC(1)
     0       0       0       8,028,643       0       8,028,643       0       21.9 %
MPM Asset Management Investors 2005 BVIII LLC
     93,953       26,366       120,319       0       120,319       0       120,319       21.9 %
Luke Evnin(1)
     0       0       0       8,148,962       0       8,148,962       8,148,962       22.2 %
Ansbert Gadicke(1)
     0       0       0       8,148,962       0       8,148,962       8,148,962       22.2 %
Nicholas Galakatos(1)
     0       0       0       8,148,962       0       8,148,962       8,148,962       22.2 %
Dennis Henner(1)
     0       0       0       8,148,962       0       8,148,962       8,148,962       22.2 %
Nicholas Simon III(1)(2)
     0       30,833       30,833       8,148,962       30,833       8,148,962       8,179,795       22.2 %
Michael Steinmetz(1)
     0       0       0       8,148,962       0       8,148,962       8,148,962       22.2 %
Kurt Wheeler(1)
     0       0       0       8,148,962       0       8,148,962       8,148,962       22.2 %
 
(1)   MPM BioVentures III GP, L.P. and MPM BioVentures III LLC own no securities of the Issuer directly. MPM BioVentures III GP, L.P. and MPM BioVentures III LLC are the direct and indirect general partners of MPM BioVentures III-QP, L.P., MPM BioVentures III, L.P., MPM BioVentures III Parallel Fund, L.P. and MPM BioVentures III GmbH & Co. Beteiligungs KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the Series A members of MPM BioVentures III LLC and managers of MPM Asset Management Investors 2005 BVIII LLC.
 
(2)   Includes 30,833 shares of common stock of the Issuer underlying options to purchase shares of common stock that have vested or will vest within 60 days of the date of this filing.
 
(3)   This percentage is calculated based upon 36,747,210 shares of the Issuer’s common stock outstanding, as adjusted pursuant to Rule 13d-3(d)(1) promulgated under the Securities Exchange Act, which is the sum of: (i) 34,961,497 shares of the Issuer’s common stock outstanding on October 30, 2009, as set forth in the Issuer’s most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 6, 2009 and (ii) 1,785,713 shares of the Issuer’s common stock issuable upon the exercise of warrants held by the MPM Entities.

 

 

(c)   The Reporting Persons sold the following shares of Common Stock in the open market pursuant to the terms of the Plan:
                     
    Date of   Number of Shares   Price Per
MPM Entity   Transaction   Sold   Share
MPM BioVentures III, L.P.
   November 5, 2009     4,387     $ 8.0025 (1)
MPM BioVentures III-QP, L.P.
   November 5, 2009     65,236     $ 8.0025 (1)
MPM BioVentures III GmbH & Co. Beteiligungs KG
   November 5, 2009     5,513     $ 8.0025 (1)
MPM BioVentures III Parallel Fund, L.P.
   November 5, 2009     1,971     $ 8.0025 (1)
MPM Asset Management Investors 2005 BVIII LLC
   November 5, 2009     1,155     $ 8.0025 (1)
MPM BioVentures III, L.P.
   November 6, 2009     14,833     $ 8.0581 (2)
MPM BioVentures III-QP, L.P.
   November 6, 2009     220,601     $ 8.0581 (2)
MPM BioVentures III GmbH & Co. Beteiligungs KG
   November 6, 2009     18,642     $ 8.0581 (2)
MPM BioVentures III Parallel Fund, L.P.
   November 6, 2009     6,664     $ 8.0581 (2)
MPM Asset Management Investors 2005 BVIII LLC
   November 6, 2009     3,908     $ 8.0581 (2)
MPM BioVentures III, L.P.
   November 9, 2009     8,522     $ 8.50 (3)
MPM BioVentures III-QP, L.P.
   November 9, 2009     126,745     $ 8.50 (3)
MPM BioVentures III GmbH & Co. Beteiligungs KG
   November 9, 2009     10,711     $ 8.50 (3)
MPM BioVentures III Parallel Fund, L.P.
   November 9, 2009     3,829     $ 8.50 (3)
MPM Asset Management Investors 2005 BVIII LLC
   November 9, 2009     2,245     $ 8.50 (3)
 
(1)   Represents the weighted average sales price for the price increments ranging from $8.00 to $8.0175.
 
(2)   Represents the weighted average sales price for the price increments ranging from $8.00 to $8.17.
 
(3)   Represents the weighted average sales price for the price increments ranging from $8.50 to $8.51.
(d)   Not applicable.
 
(e)   Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
     “Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer” is hereby amended by adding the following to the end thereof:
     On September 21, 2009, the Reporting Persons entered into a Rule 10b5-1 sales plan with a broker to sell a portion of their holdings of the Issuer’s Common Stock, with such shares to be sold in separate tranches at different specified market prices ranging from $8.00 to $9.50. The Plan was adopted in accordance with the Issuer’s insider trading policy and is intended to comply with the provisions of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

 

 

Item 7. Material to Be Filed as Exhibits.
A. Form of Securities Purchase Agreement between the Issuer and certain Purchasers, dated February 1, 2006 (Incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed on February 3, 2006 (SEC File No. 0-16614)).
B. Form of Note and Warrant Purchase Agreement between the Issuer and certain Purchasers, dated February 1, 2006 (Incorporated by reference to Exhibit 10.2 to the Issuer’s Current Report on Form 8-K filed on February 3, 2006 (SEC File No. 0-16614)).
C. Joint Filing Statement.

 

 

SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: November 17, 2009
                       
MPM BIOVENTURES III, L.P.   MPM BIOVENTURES III-QP, L.P.
 
                    
By:   MPM BioVentures III GP, L.P.,   By:   MPM BioVentures III GP, L.P.,
    its General Partner       its General Partner
 
                    
By:   MPM BioVentures III LLC,   By:   MPM BioVentures III LLC,
    its General Partner       its General Partner
 
                    
By:   /s/ Luke Evnin   By:   /s/ Luke Evnin
             
 
  Name:   Luke Evnin       Name:   Luke Evnin
 
  Title:   Series A Member       Title:   Series A Member
                       
MPM BIOVENTURES III PARALLEL FUND, L.P.   MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG
 
                    
By:   MPM BioVentures III GP, L.P.,   By:   MPM BioVentures III GP, L.P.,
    its General Partner       in its capacity as the Managing Limited Partner
 
                    
By:   MPM BioVentures III LLC,   By:   MPM BioVentures III LLC,
    its General Partner       its General Partner
 
                    
By:   /s/ Luke Evnin   By:   /s/ Luke Evnin
             
 
  Name:   Luke Evnin       Name:   Luke Evnin
 
  Title:   Series A Member       Title:   Series A Member
 
                    
                       
MPM ASSET MANAGEMENT INVESTORS 2005 BVIII LLC   MPM BIOVENTURES III GP, L.P.

By:		  
/s/ Luke Evnin		   By:   MPM BioVentures III LLC,
its General Partner
    Name:   Luke Evnin      
    Title:   Manager   By:   /s/ Luke Evnin
                 
 
              Name:   Luke Evnin
 
              Title:   Series A Member
                       
MPM BIOVENTURES III LLC            
 
                    
By:   /s/ Luke Evnin       /s/ Luke Evnin
             
    Name:   Luke Evnin       Luke Evnin
 
  Title:   Series A Member            
 
                    
    /s/ Ansbert Gadicke       /s/ Nicholas Galakatos
             
    Ansbert Gadicke       Nicholas Galakatos

 

 

                       
    /s/ Michael Steinmetz       /s/ Kurt Wheeler
             
    Michael Steinmetz       Kurt Wheeler
 
                    
    /s/ Nicholas Simon III       /s/ Dennis Henner
             
    Nicholas Simon III       Dennis Henner

 

 

SCHEDULE I
General Partners/Members:
Luke Evnin
c/o MPM Asset Management
The John Hancock Tower
200 Clarendon Street, 54th Floor
Boston, Massachusetts 02116
Principal Occupation: Series A member of the general partner of the general partner of MPM BioVentures III-QP, L.P., MPM BioVentures III, L.P., MPM BioVentures III Parallel Fund, L.P. and MPM BioVentures III GmbH & Co. Beteiligungs KG and manager of MPM Asset Management Investors 2005 BVIII LLC
Citizenship: USA
Ansbert Gadicke
c/o MPM Asset Management
The John Hancock Tower
200 Clarendon Street, 54th Floor
Boston, Massachusetts 02116
Principal Occupation: Series A member of the general partner of the general partner of MPM BioVentures III-QP, L.P., MPM BioVentures III, L.P., MPM BioVentures III Parallel Fund, L.P. and MPM BioVentures III GmbH & Co. Beteiligungs KG and manager of MPM Asset Management Investors 2005 BVIII LLC
Citizenship: USA
Nicholas Galakatos
c/o MPM Asset Management
The John Hancock Tower
200 Clarendon Street, 54th Floor
Boston, Massachusetts 02116
Principal Occupation: Series A member of the general partner of the general partner of MPM BioVentures III-QP, L.P., MPM BioVentures III, L.P., MPM BioVentures III Parallel Fund, L.P. and MPM BioVentures III GmbH & Co. Beteiligungs KG and manager of MPM Asset Management Investors 2005 BVIII LLC
Citizenship: USA
Michael Steinmetz
c/o MPM Asset Management
The John Hancock Tower
200 Clarendon Street, 54th Floor
Boston, Massachusetts 02116
Principal Occupation: Series A member of the general partner of the general partner of MPM BioVentures III-QP, L.P., MPM BioVentures III, L.P., MPM BioVentures III Parallel Fund, L.P. and MPM BioVentures III GmbH & Co. Beteiligungs KG and manager of MPM Asset Management Investors 2005 BVIII LLC
Citizenship: USA
Kurt Wheeler
c/o MPM Asset Management
The John Hancock Tower
200 Clarendon Street, 54th Floor
Boston, Massachusetts 02116
Principal Occupation: Series A member of the general partner of the general partner of MPM BioVentures III-QP, L.P., MPM BioVentures III, L.P., MPM BioVentures III Parallel Fund, L.P. and MPM BioVentures III GmbH & Co. Beteiligungs KG and manager of MPM Asset Management Investors 2005 BVIII LLC
Citizenship: USA

 

 

Nicholas Simon III
c/o MPM Asset Management
The John Hancock Tower
200 Clarendon Street, 54th Floor
Boston, Massachusetts 02116
Principal Occupation: Series A member of the general partner of the general partner of MPM BioVentures III-QP, L.P., MPM BioVentures III, L.P., MPM BioVentures III Parallel Fund, L.P. and MPM BioVentures III GmbH & Co. Beteiligungs KG and manager of MPM Asset Management Investors 2005 BVIII LLC
Citizenship: USA
Dennis Henner
c/o MPM Asset Management
The John Hancock Tower
200 Clarendon Street, 54th Floor
Boston, Massachusetts 02116
Principal Occupation: Series A member of the general partner of the general partner of MPM BioVentures III-QP, L.P., MPM BioVentures III, L.P., MPM BioVentures III Parallel Fund, L.P. and MPM BioVentures III GmbH & Co. Beteiligungs KG and manager of MPM Asset Management Investors 2005 BVIII LLC
Citizenship: USA

 

 

Exhibit Index
A. Form of Securities Purchase Agreement between the Issuer and certain Purchasers, dated February 1, 2006 (Incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed on February 3, 2006 (SEC File No. 0-16614)).
B. Form of Note and Warrant Purchase Agreement between the Issuer and certain Purchasers, dated February 1, 2006 (Incorporated by reference to Exhibit 10.2 to the Issuer’s Current Report on Form 8-K filed on February 3, 2006 (SEC File No. 0-16614)).
C. Joint Filing Statement.

 

EX-99.C 2 f54114exv99wc.htm EX-99.C exv99wc
Exhibit C
JOINT FILING STATEMENT
     The undersigned hereby agree that this Schedule 13D/A with respect to the Common Stock of Poniard Pharmaceuticals, Inc. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
Dated: November 17, 2009
                       
MPM BIOVENTURES III, L.P.   MPM BIOVENTURES III-QP, L.P.
 
                    
By:   MPM BioVentures III GP, L.P.,   By:   MPM BioVentures III GP, L.P.,
    its General Partner       its General Partner
 
                    
By:   MPM BioVentures III LLC,   By:   MPM BioVentures III LLC,
    its General Partner       its General Partner
 
                    
By:   /s/ Luke Evnin   By:   /s/ Luke Evnin
             
 
  Name:   Luke Evnin       Name:   Luke Evnin
 
  Title:   Series A Member       Title:   Series A Member
                       
MPM BIOVENTURES III PARALLEL FUND, L.P.   MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG
 
                    
By:   MPM BioVentures III GP, L.P.,   By:   MPM BioVentures III GP, L.P.,
    its General Partner       in its capacity as the Managing Limited Partner
 
                    
By:   MPM BioVentures III LLC,   By:   MPM BioVentures III LLC,
    its General Partner       its General Partner
 
                    
By:   /s/ Luke Evnin   By:   /s/ Luke Evnin
             
 
  Name:   Luke Evnin       Name:   Luke Evnin
 
  Title:   Series A Member       Title:   Series A Member
 
                    
                       
MPM ASSET MANAGEMENT INVESTORS 2005 BVIII LLC   MPM BIOVENTURES III GP, L.P.

By:		  
/s/ Luke Evnin		   By:   MPM BioVentures III LLC,
its General Partner
    Name:   Luke Evnin      
    Title:   Manager   By:   /s/ Luke Evnin
                 
 
              Name:   Luke Evnin
 
              Title:   Series A Member
                       
MPM BIOVENTURES III LLC            
 
                    
By:   /s/ Luke Evnin       /s/ Luke Evnin
             
    Name:   Luke Evnin       Luke Evnin
 
  Title:   Series A Member            

 

 

                       
    /s/ Ansbert Gadicke       /s/ Nicholas Galakatos
             
    Ansbert Gadicke       Nicholas Galakatos
 
                    
    /s/ Michael Steinmetz       /s/ Kurt Wheeler
             
    Michael Steinmetz       Kurt Wheeler
 
                    
    /s/ Nicholas Simon III       /s/ Dennis Henner
             
    Nicholas Simon III       Dennis Henner

 

-----END PRIVACY-ENHANCED MESSAGE-----